Dr. David Fajgenbaum

And it doesn't turn out that it works for everyone.

But for those 18% of patients, it's everything, right?

Because the drug was already there.

It's not like you had to create a new drug.

It's already there.

You just had to give it to someone.

And so that, to me, means the world.

And that was also, that was the first time that we went into a disease outside of Castleman's or related to Castleman's.

It was sort of the first time it was like, oh my gosh, we can do this outside of the diseases that we're focused on, which was so important for us to want to keep pushing this mission forward.

Another one is a young girl named Kyla who has Castleman's.

She has the same subtype of Castleman's as me, the really deadly one.

She spent about a year in the hospital.

Nothing was working at Chicago, Lurie Children's Hospital, and nothing was working.

And one day her doctor called me late.

It was, I remember during the pandemic, it was like 8 p.m.

one night, and said, you know, we've been trying things for a year, nothing's working.

The drug that I'm on, serolimus, didn't work.

Chemotherapy wasn't even working for her.

You know, is there anything you can try?

And just a couple weeks before, a couple members of my lab had discovered that this one part of the immune system was in overdrive, not mTOR, but something called JAK.